Zepbound for Sleep Apnea: The First Drug FDA-Approved for OSA (2026)

In December 2024 the FDA approved Zepbound (tirzepatide) to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first prescription drug ever approved to treat OSA, a condition that until then was managed mechanically with CPAP, oral appliances, weight loss, or surgery rather than with a medication.^[1] The approval was built on the phase 3 SURMOUNT-OSA program, published in the New England Journal of Medicine, which showed that tirzepatide produced large, clinically meaningful reductions in the apnea-hypopnea index (AHI) — the standard measure of how many times an hour breathing pauses or shallows during sleep — in patients both using and not using a CPAP machine, alongside substantial weight loss.^[2] Zepbound is the same molecule as Mounjaro; it is a dual GIP/GLP-1 receptor agonist, and it appears to work for OSA largely by reducing the excess body weight that drives the airway collapse. This guide explains what the trial showed, who is a candidate, how it is dosed and accessed, what the OSA approval means for insurance coverage, and the gastrointestinal side-effect profile to expect. It is general educational information, not medical advice — and crucially, it is not a signal to stop CPAP on your own. Your prescriber and sleep specialist manage your care.

What the FDA approved — and why it's a milestone

In December 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, to be used together with a reduced-calorie diet and increased physical activity.^[1] What makes this a landmark is the word first: before this approval there was no prescription medication indicated to treat OSA at all. OSA — in which the upper airway repeatedly collapses or narrows during sleep, causing breathing to pause or shallow, oxygen levels to dip, and sleep to fragment — was treated mechanically and behaviorally: continuous positive airway pressure (CPAP), oral appliances, weight management, and in some cases surgery. Zepbound is the first drug to enter that toolkit.^[1]

It is important to read the indication precisely. Zepbound is approved for OSA in adults who also have obesity — not for OSA in everyone, and not for people of normal weight whose apnea is driven by jaw or airway anatomy rather than weight. The mechanism here is largely indirect: tirzepatide is a powerful weight-loss medicine, and excess weight (particularly fat deposition around the neck and upper airway) is one of the strongest drivers of obstructive sleep apnea. By producing substantial weight loss, the drug reduces the load on the airway, and AHI falls with it.^[2] That framing matters for the rest of this article — who benefits, and why CPAP is not simply replaced.

What the SURMOUNT-OSA trial showed

The approval rests on SURMOUNT-OSA, a phase 3 program reported by Malhotra and colleagues in the New England Journal of Medicine in 2024. It ran as two parallel trials of adults with obesity and moderate-to-severe OSA: one enrolled people not using CPAP (or other positive airway pressure) therapy, and the other enrolled people who were using it. In both, participants were randomized to the maximum tolerated dose of tirzepatide or placebo for 52 weeks, on top of lifestyle measures. The primary endpoint was the change in the apnea-hypopnea index (AHI) — the number of apnea and hypopnea events per hour of sleep, the core severity measure for OSA.^[2]

The reductions were large and clinically meaningful. Among participants not using positive airway pressure therapy, AHI fell by a mean of about 25 events per hour with tirzepatide versus about 5 with placebo, an estimated treatment difference of roughly 20 fewer events per hour. Among those using positive airway pressure therapy, AHI fell by about 29 events per hour with tirzepatide versus about 5.5 with placebo, an estimated treatment difference of roughly 24 fewer events per hour. Both differences were highly statistically significant (P<0.001).^[2] To put that in perspective, a drop of that magnitude is often enough to shift someone from severe toward mild OSA — or, for some participants, toward disease that would no longer meet the threshold for diagnosis.

The benefit did not stop at AHI. Tirzepatide also produced substantial weight loss and improvements in several OSA-related and cardiometabolic measures reported in the trial, including nighttime oxygenation, body weight, high-sensitivity C-reactive protein (an inflammatory marker), and blood pressure, along with patient-reported sleep impairment.^[2] The consistent picture — AHI down, weight down, oxygenation and inflammation and blood pressure improved — is what supported a treatment indication rather than a narrow one.

Is Zepbound a replacement for CPAP?

For most people, no — not on its own, and not without medical guidance. This is the single most important framing point. Zepbound is approved as a treatment for OSA in adults with obesity, and the SURMOUNT-OSA data are genuinely impressive, but the approval is not an instruction to throw out your CPAP machine. Notably, one entire arm of the trial studied people who continued using positive airway pressure therapy while taking tirzepatide — the drug was tested alongside CPAP, not purely as a substitute for it.^[2]

Whether you can reduce or eventually stop CPAP is a clinical decision your sleep specialist makes, ideally confirmed with a repeat sleep study after meaningful weight loss — not something to do unilaterally because your AHI should be improving. Stopping CPAP prematurely can leave dangerous, untreated apnea in place, with its associated risks to the heart, daytime alertness, and driving safety. The practical takeaway: think of Zepbound as a powerful new tool that can lower OSA severity by reducing the weight that drives it, used within a sleep-medicine plan — and keep using CPAP exactly as prescribed unless and until your clinician tells you otherwise.

Who is a candidate?

The approved population is adults with moderate-to-severe obstructive sleep apnea who also have obesity, using the drug alongside a reduced-calorie diet and increased physical activity.^[1] In practice, a candidate is generally someone who:

• Is an adult with a diagnosis of moderate-to-severe OSA, typically confirmed by a sleep study (in-lab polysomnography or a validated home sleep test).^[1]
• Also meets the obesity criterion — the indication is specifically for OSA with obesity, reflecting that the drug works by reducing airway-loading weight.^[1]
• Is being managed within a plan that includes diet and physical activity, and — where relevant — ongoing CPAP or other sleep-medicine care, rather than as a stand-alone swap for those measures.^[1][2]
• Does not have a contraindication to tirzepatide; the label carries a boxed warning about thyroid C-cell tumors seen in rodents, and the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.^[3]

People whose apnea is driven mainly by airway or jaw anatomy rather than weight, or whose OSA is mild, fall outside this specific indication — though a prescriber may still consider tirzepatide for an appropriate separate obesity indication. The decision, and the diagnosis that anchors it, belong with your clinician and sleep specialist.

Same molecule as Mounjaro — dosing and access

Zepbound and Mounjaro are the same active ingredient — tirzepatide, a once-weekly subcutaneous injection. The two are marketed under different brand names for different indications (Mounjaro for type 2 diabetes; Zepbound for weight management and now OSA in adults with obesity), but the molecule and the way it is taken are the same. Like other GIP/GLP-1 medicines, tirzepatide is titrated upward in steps over several weeks — starting low and increasing on a schedule to the maintenance or maximum tolerated dose — to improve tolerability, and it is available in single-dose pens and vials per the label.^[3]

Access runs through a prescriber, with the usual GLP-1/GIP requirements: a clinical evaluation, an appropriate diagnosis, and follow-up. Because Zepbound now carries a specific OSA indication, a sleep-apnea diagnosis can itself be the basis for the prescription in eligible adults with obesity — your clinician determines the right dose, the titration pace, and how it fits with any existing CPAP plan. Do not adjust the dose or skip the titration steps on your own.

Cost and insurance coverage

Tirzepatide is an expensive brand-name medication, and out-of-pocket cost depends heavily on insurance, manufacturer savings programs, and whether you are buying a branded pen or a vial. We do not quote prices here because they change frequently and vary by plan and pharmacy. What the OSA approval did change is the coverage pathway: a distinct, FDA-approved medical indication for obstructive sleep apnea gives plans a recognized basis to cover the drug for that condition, which historically has been easier to get covered than weight loss alone — many plans exclude or restrict anti-obesity medications, but treat a diagnosed disease like OSA differently.^[1]

In practical terms, that means an adult with obesity and a documented moderate-to-severe OSA diagnosis may have a more straightforward route to coverage than someone seeking the same drug purely for weight management — though prior authorization, step therapy, and plan-specific rules still apply. The only reliable way to know your cost is to check with your insurer and pharmacist; your prescriber's office can also help with prior-authorization paperwork that documents the OSA indication.

Side effects to expect

The side-effect profile is the familiar tirzepatide one — predominantly gastrointestinal, especially during dose escalation. The most commonly reported reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, decreased appetite, and injection-site reactions, and these tend to be most pronounced in the early weeks and after each dose increase, easing as the body adapts.^[3] Most are mild to moderate and manageable with a slower titration, hydration, and dietary adjustments under your prescriber's guidance.

The label also carries a boxed warning about thyroid C-cell tumors observed in rodents, with contraindications in people who have a personal or family history of medullary thyroid carcinoma or MEN 2, plus warnings about pancreatitis, gallbladder problems, kidney injury (often via dehydration from GI losses), and — when combined with insulin or a sulfonylurea — hypoglycemia.^[3] For a deeper look at the day-to-day reactions and how they're managed, see our tirzepatide constipation guide and our Mounjaro fatigue guide, since Zepbound and Mounjaro share the same molecule and therefore the same side-effect picture.